Table 2.
Sunitinib treatment outcome stratified by status of clinical trial participation
| Treatment outcome | Clinical trial participants (n=49) | Matched clinical trial non-participants (n=49) | p-value | HR (95% CI) |
|---|---|---|---|---|
| Response rate | Odds ratio, 1.2 | |||
| Partial response | 26 (53) | 20 (41) | 0.63 | |
| Stable disease | 13 (27) | 16 (33) | ||
| Disease progression within 12 weeks of the start of sunitinib | 10 (20) | 13 (26) | ||
| Median PFS (mo) | 10 | 11 | 0.84 | 0.96 (0.68-1.19) |
| Median OS (mo) | 23 | 24 | 0.89 | 0.97 (0.72-1.13) |
Values are presented as number (%) unless otherwise indicated. HR, hazard ratio; CI, confidence interval; PFS, progression free survival; OS, overall survival.